Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance

Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy. Mutations in the kinase domain of BCR::ABL1 are the most extensively studied mechanism of TKI resistance in CML, but BCR::AB...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimaru, Ryo, Minami, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530602/
https://www.ncbi.nlm.nih.gov/pubmed/37762109
http://dx.doi.org/10.3390/ijms241813806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530602/
https://www.ncbi.nlm.nih.gov/pubmed/37762109
http://dx.doi.org/10.3390/ijms241813806

Ejemplares similares